Bmc Nephrol
-
Randomized Controlled Trial Multicenter Study
Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial.
The main hypothesis of this study is that Oxpentifylline administration will effectively treat erythropoietin- or darbepoietin-resistant anaemia in chronic kidney disease patients. ⋯ This investigator-initiated multicentre study has been designed to provide evidence to help nephrologists and their chronic kidney disease patients determine whether oxpentifylline represents a safe and effective strategy for treating erythropoiesis stimulating agent resistance in chronic kidney disease.